BJH - volume 6, issue Abstract Book BHS, january 2015
D. Dierickx MD, PhD, A. van Mellaert , L. Smets , G. Verhoef MD, PhD, P. Clement MD, PhD, P. Demaerel , T. Tousseyn MD, PhD, M. Delforge MD, PhD, T. Devos MD, PhD, A. Janssens MD, PhD, J. Maertens MD, PhD, H. Schoemans MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
D. Dierickx MD, PhD, D. Gullentops , G. Verhoef MD, PhD, S. Vanderschueren MD, PhD, T. Tousseyn MD, PhD, O. Gheyssens , M. Delforge MD, PhD, T. Devos MD, PhD, A. Janssens MD, PhD, J. Maertens MD, PhD, H. Schoemans MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
D. Dierickx MD, PhD, K. Saevels MD, G. Verhoef MD, PhD, M. Delforge MD, PhD, T. Devos MD, PhD, A. Janssens MD, PhD, J. Maertens MD, PhD, H. Schoemans MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
P. Vandenberghe MD, PhD, I. Wlodarska , T. Tousseyn MD, PhD, L. Dehaspe , D. Dierickx MD, PhD, M. Verheecke , A. Uyttebroeck MD, PhD, O. Bechter , M. Delforge MD, PhD, V. Vandecaveye , N. Brison , G.E.G. Verhoef , E. Legius , F. Amant , J.R. Vermeesch
BJH - volume 5, issue 4, december 2014
M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, PhD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, KL. Wu MD, PhD, C. Doyen MD, R. Schots MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).
(BELG J HEMATOL 2014;5(4):125–36)
Read moreBJH - volume 5, issue 2, june 2014
M. Delforge MD, PhD
During the last decade, thalidomide, lenalidomide and bortezomib have significantly improved the outcome for patients with multiple myeloma. Although still frequently referred to as ‘novel agents’, a newer generation of more potent proteasome inhibitors and immunomodulatory drugs are expected to enter the myeloma clinic in the near future. New proteasome inhibitors like carfilzomib have shown unprecedented anti-myeloma activity, particularly when combined with lenalidomide and dexamethasone. Other proteasome inhibitors under development will be more patient-friendly by becoming orally available. In the class of immunomodulatory drugs, it is expected that pomalidomide will be registered in the near future for refractory myeloma patients, based on convincing phase III data. Finally, after many years of research, myeloma also has its monoclonal antibodies. Daratumumab and elotuzumab are evaluated in several clinical studies. All these new agents will not replace the current, yet not old, anti-myeloma drugs. The major challenge will become to prove that optimal drug sequencing or combination, guided by science and clinical experience, will continue to prolong the life expectancy of patients with multiple myeloma.
(BELG J HEMATOL 2014;5(2):55–9)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
V. Roobrouck , S. Chakraborty , T. Vanwelden , K. Sels , E. Lazarri , S. Pandey , N. Boeckx MD, PhD, M. Delforge MD, PhD, C. Verfaillie
Top
